Aerie Pharmaceuticals is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product, Rhopressa, is a once-daily triple-action eye drop that has demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in clinical trials. The company’s second product, Rocklatan, is a once-daily quadruple-action single drop combination of Rhopressa plus latanoprost, that has also demonstrated the ability to reduce IOP in clinical trials. Aerie is also advancing a preclinical pipeline of implantable treatments for ocular disorders that will enter the clinic in 2019.